Serum uric acid and lipid levels while taking topiramate for migraine

Basit Öğe Kaydı
dc.contributor.authorKoçer, Abdulkadir
dc.contributor.authorDikici, Süber
dc.contributor.authorAtakay, Selçuk
dc.contributor.authorOkuyucu, Şefika
dc.date.accessioned2020-04-30T23:31:54Z
dc.date.available2020-04-30T23:31:54Z
dc.date.issued2008
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionKocer, Abdulkadir/0000-0003-2866-555Xen_US
dc.descriptionWOS: 000257483200008en_US
dc.descriptionPubMed: 18179568en_US
dc.description.abstractObjective.-Topiramate (TPM) therapies for epilepsy or migraine are long-time therapies with unknown mechanisms and special side effects. TPM influences cholesterol (TC) and lipoprotein serum levels. In addition, TPM may cause uric acid (UA) stone formation. Material and Methods.-Serum UA, TC, and triglyceride (TG) levels were measured in 53 migraine patients receiving TPM and in 44 age- and sex-matched controls. Compared with controls, patients on TPM showed significantly higher UA and nonsignificantly higher TC and TG values. We recorded pre- and posttreatment levels of UA, TC, and TG levels in 23 patients. Results.-We found increased serum levels of UA with TPM use (P < .01). There was a significant and positive correlation between serum UA levels and male gender (P < .01).The changes in serum UA levels before and after TPM treatment differed significantly (P < .01). Conclusion.-Our results suggest a need for monitoring serum UA levels in patients receiving TPM. We should perhaps prescribe a low-UA diet and advice to drink much more water in these patients.en_US
dc.identifier.doi10.1111/j.1526-4610.2007.01008.xen_US
dc.identifier.endpage1060en_US
dc.identifier.issn0017-8748
dc.identifier.issn1526-4610
dc.identifier.issue7en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1056en_US
dc.identifier.urihttps://doi.org/10.1111/j.1526-4610.2007.01008.x
dc.identifier.urihttps://hdl.handle.net/20.500.12684/4521
dc.identifier.volume48en_US
dc.identifier.wosWOS:000257483200008en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofHeadacheen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecturic aciden_US
dc.subjectcholesterolen_US
dc.subjecttriglycerideen_US
dc.subjecttopiramateen_US
dc.subjectmigraineen_US
dc.subjectantiepileptic treatmenten_US
dc.titleSerum uric acid and lipid levels while taking topiramate for migraineen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
4520.pdf
Boyut:
57 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu